US Contract Research Organization (CRO) industry: UBS sees a CRO demand recovery, but favors IQV and CRL as valuations constrain broad sector upside

Overview

This is UBS's initiation and resumption of coverage across the US CRO industry and selected clinical-technology companies. The report argues that biotech funding, R&D spending, and bookings are improving, but structural outsourcing-mix changes and valuation constraints make company-specific execution and catalysts more important than a broad sector call.

Core views

UBS takes a constructive but selective view of the CRO industry. Its model of 2,000 biopharma companies forecasts global R&D spending growth of 5.2% annually from 2025 to 2030, versus 5.9% from 2010 to 2025. Small biotech is expected to lead reported R&D growth at 6.6% annually, or 8.2% organically after adjusting for M&A; mid-sized biotech is forecast at 6.2% and large pharma at 4.3%. UBS estimates that outsourcing penetration can add zero to 100bp to underlying R&D growth, producing CRO market growth of 5.2%-6.2% per year through 2030. This is below the industry's historical 7%-8% growth because UBS expects outsourcing to contribute less than the historical roughly 200bp. The principal structural constraint is the shift from Full Service Outsourcing (FSO) to Functional Service Provider (FSP) arrangements. FSO places end-to-end study execution with the CRO, while FSP retains more trial-management responsibility at the sponsor and uses CRO staff for specific functions. UBS's survey of 50 biopharma sponsors found 44% had increased FSP use over the prior 12 months, compared with 24% increasing FSO. Among large pharma, 50% reported greater FSP use versus 25% for FSO. UBS notes that FSP pricing may be 20%-30% lower and operating margins 300-500bp lower than FSO, while the mix shift may persist as a revenue and margin headwind for two to three years because clinical programs have long durations. The survey suggests FSO and FSP adoption could become more balanced over the next 12 months, but UBS does not expect this to flow rapidly into reported revenue or margins. The report identifies biotech as the near-term demand driver. Trailing-12-month biotech funding increased 87% year-on-year through August, and UBS's historical analysis finds that funding trends are closely associated with CRO bookings growth and book-to-bill ratios. UBS expects the funding recovery to support higher bookings in 2H26 and 1H27; the clinical-CRO group averaged a 1.23x book-to-bill in 2Q26, with a 1.31x weighted average. Private CRO checks also point to stronger bookings, with some companies reporting book-to-bill above 2.0x compared with near or below 1.0x 12-18 months earlier. Biotech is leading the recovery, while large-pharma activity is stabilizing more gradually after portfolio resets, loss-of-exclusivity pressures, policy uncertainty, and FDA-related uncertainty. UBS views AI as a real long-term risk but not a material near-term earnings threat. AI could reduce labor hours and revenue per trial, especially in medical writing and biostatistics, which UBS estimates represent roughly 15% of revenue in a typical full-service Phase III study. Clinical CROs are more exposed than preclinical providers because clinical development has more administrative processes. However, sponsor adoption is slow, regulators' acceptance remains uncertain, and most industry checks expect little material impact on CRO revenue or margins over the next three years. In the sponsor survey, 36% expected AI to increase outsourcing and 10% expected it to decrease outsourcing, while 50% expected no impact. Forty-four percent expected AI to improve both the number and quality of molecules pursued; UBS believes greater program volume and better success rates could partly offset lower revenue per trial. More than half of respondents did not expect significant R&D cost savings for at least three years. The valuation conclusion tempers the positive fundamentals. CROs trade at roughly 22x next-twelve-month P/E, up from 15x in February, and at about 1.04x the market's next-twelve-month P/E, below the historical 1.15x relative average. UBS expects improving book-to-bill to support modest additional multiple upside, but argues that lower forward growth, FSP and pricing pressure, and AI concerns narrow the re-rating runway. The firm expects book-to-bill near roughly 1.20x to support mid-single-digit rather than historical high-single-digit revenue growth because backlog burn rates are declining. Industry-wide EBITDA margin expansion is expected to be flat to modest beyond FY27, although certain companies have identifiable company-specific margin drivers. IQVIA is UBS's preferred clinical CRO and is resumed at Buy with a $345 target. UBS expects book-to-bill to rise from 1.22x in 2Q26 to 1.23x in 3Q26 and 1.25x in 4Q26, with FY27 at 1.23x versus consensus at 1.19x. It forecasts Research & Development Solutions growth of 5.9% in FY26 and 6.2% in FY27, modestly above consensus, and total revenue CAGR of 6.5% from FY25 through FY30. UBS cites improving biotech demand, IQV's strong win rate and market-share gains, and survey evidence that IQV received 22% of combined first- and second-choice CRO votes. The firm expects 20-30bp of annual margin improvement from operating leverage and AI-related SG&A savings. At 19.6x next-twelve-month P/E, below the CRO median of 22x, UBS sees valuation as reasonable; its $345 target uses a 22x next-twelve-month-plus-12-month P/E multiple. Charles River is also resumed at Buy with a $357 target. UBS's core thesis is that internalizing non-human-primate supply through the KF acquisition can reduce annualized sourcing costs by about $40 million by FY27, driving more than 160bp of Discovery and Safety Assessment operating-margin expansion and approximately $0.64 of EPS accretion, above management's $0.60 target. UBS estimates an 80% internally sourced and 20% external mix would reduce annualized NHP costs from about $155 million to about $115 million. Improving biotech demand and potentially firmer NHP-study pricing are additional upside, though UBS does not assume a repeat of 2022-2023 price inflation. Its FY27 and FY28 adjusted EPS estimates are 5% and 8% above consensus, respectively. UBS flags valuation as the principal risk: CRL trades at 24x next-twelve-month P/E, above the peer median of 20x, so the thesis requires execution on visible cost savings and earnings upside. UBS initiates Fortrea at Neutral with a $22 target. While it expects FTRE to benefit from better sector demand, UBS forecasts FY27 revenue growth of 2.2% versus consensus at 3.1%, followed by about 4% annual growth beginning in FY28, below its 5.2%-6.2% sector outlook. FTRE reported peer-low 1.06x book-to-bill in 2Q26; UBS expects 1.10x in 3Q26 and long-term book-to-bill of 1.10x-1.15x, while estimating it would need closer to 1.20x to grow in line with the industry. The firm sees structural margin limits from the lack of an internal central lab, lower-margin FSP backlog, limited remaining cost cuts, and the need to retain staff to protect delivery quality. FTRE's 7.0% FY25 EBITDA margin was the lowest among CRO peers. Although UBS views deleveraging from current net leverage of 4.3x as viable as free cash flow normalizes, it notes that the 12.6% trailing FCF yield is flattered by collections catch-up after ERP disruption. Its $22 target uses a 12x next-twelve-month-plus-12-month EV/EBITDA multiple. For the other covered stocks, UBS assigns Neutral ratings because favorable industry exposure is offset by execution or valuation concerns. ICLR's $195 target reflects its 15x next-twelve-month-plus-12-month P/E, but UBS sees client-specific challenges, market-share pressure, higher FSP mix, pricing headwinds, and uncertainty around financial investigations; it forecasts EBITDA margin of 17% by FY27 but does not expect a return to COVID-era 20%+ margins. MEDP has 95% biotech exposure and could sustain around 9% long-term revenue growth, but its 33x next-twelve-month P/E and booking volatility limit risk-reward; its backlog rose only 3.6% from 1Q24 while revenue increased 38%, making pre-backlog conversion critical. CERT's $10 target uses a 13x EV/EBITDA multiple, but UBS forecasts only 7% long-term Software growth, approximately 2.5% Services growth, and around 5% total long-term growth because biosimulation remains a niche capability; cost savings are partly offset by stranded overhead and investment needs, while AI-driven demand remains too early to underwrite.

Analysis framework

UBS combines a 2,000-company biopharma R&D model, a survey of 50 biopharma sponsors, historical analysis of biotech funding and CRO bookings, channel checks with public and private CROs, industry-expert discussions, company financial forecasts, peer valuation comparisons, and reverse DCF analysis. It then applies company-specific operating and valuation assumptions to distinguish preferred names from neutral-rated peers.

Methodology notes

• Industry AnalysisSupply-demand framework

  Biopharma R&D growth, biotech funding, outsourcing penetration, FSP/FSO mix, and CRO bookings

  UBS links sponsor funding and R&D budgets to CRO demand, then adjusts the revenue outlook for the mix and degree of outsourced work.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Biopharma sponsor spending flowing through to CRO bookings, backlog, revenue, and margins

  The report treats biotech funding and sponsor R&D as leading indicators whose effect moves through bookings and book-to-bill before appearing in CRO revenue.

• Valuation methodsP/E and PEG Valuation

  P/E-based price targets for profitable, cash-generative CROs

  UBS uses next-twelve-month-plus-12-month P/E multiples for IQV, CRL, ICLR, and MEDP, comparing each with peer and historical valuation levels.

• Valuation methodsEV/EBITDA valuation

  EV/EBITDA valuation for FTRE and CERT

  UBS uses EV/EBITDA for leveraged FTRE and clinical-technology company CERT rather than P/E.

• Valuation methodsDCF (Discounted Cash Flow)

  Reverse DCF

  UBS uses reverse DCFs to infer the revenue growth and margin expansion embedded in current market valuations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• IQVIA (IQV)

  Preferred clinical CRO and Buy-rated sector top pick

  Strengths

  Market-share gains, strong biotech positioning, expected book-to-bill above 1.20x, data infrastructure, and potential AI-related SG&A savings.

  Weaknesses

  FSP mix remains a gross-margin headwind.

  Comparison

  Trades at 19.6x NTM P/E versus a CRO peer median of 22x.

  Risks

  Failure to sustain book-to-bill above 1.20x or to convert improving biotech demand into bookings.

• Charles River Laboratories (CRL)

  Buy-rated preclinical CRO

  Strengths

  Internal NHP sourcing is expected to create visible cost savings and DSA margin expansion; biotech demand is improving.

  Weaknesses

  Thesis depends on executing sourcing integration and realizing projected savings.

  Comparison

  Trades at 24x NTM P/E versus a CRO peer median of 20x.

  Risks

  Premium valuation and elevated expectations leave less room for earnings-execution shortfalls.

• Fortrea Holdings (FTRE)

  Newly initiated Neutral-rated clinical CRO

  Strengths

  Potential deleveraging and improving biotech demand could support recovery.

  Weaknesses

  Soft bookings, low margin, FSP-heavy backlog, no internal central lab, and limited remaining cost-cutting opportunities.

  Comparison

  Trades at an industry-low 11.7x NTM EV/EBITDA, which UBS views as appropriate for its weaker outlook.

  Risks

  Client churn, market-share losses, weak book-to-bill, elevated leverage, and slower revenue growth.

• ICON Plc (ICLR)

  Neutral-rated clinical CRO

  Strengths

  Low valuation relative to peers and potential return to 17% EBITDA margin by FY27.

  Weaknesses

  Client challenges, FSP mix, pricing pressure, and market-share uncertainty.

  Comparison

  Trades near 15x NTM P/E, below the CRO peer median of 22x.

  Risks

  Bookings could weaken after elevated 2Q26 book-to-bill and financial-investigation uncertainty may persist.

• Medpace (MEDP)

  Neutral-rated biotech-focused clinical CRO

  Strengths

  Approximately 95% biotech exposure and potential to sustain around 9% long-term revenue growth.

  Weaknesses

  Backlog coverage has declined and future growth depends on pre-backlog converting to active trials.

  Comparison

  Trades at 33x NTM P/E, the highest CRO peer valuation.

  Risks

  Bookings volatility, cancellations, and a high valuation that limits multiple upside.

• Certara (CERT)

  Neutral-rated clinical technology company

  Strengths

  Biosimulation and MIDD capabilities; end markets are improving.

  Weaknesses

  Software adoption remains limited, growth visibility is low, and cost savings are offset by stranded costs and investment.

  Comparison

  Target uses 13x NTM+12Me EV/EBITDA, in line with current valuation and the ClinTech peer median.

  Risks

  Software growth may remain muted and AI-related demand may take longer to become material.

Key data

• Global biopharma R&D growth forecast5.2% CAGR, 2025-2030Below the 5.9% CAGR recorded from 2010-2025.
• CRO market growth forecast5.2%-6.2% per year through 2030Assumes zero to 100bp contribution from outsourcing penetration.
• TTM biotech funding+87% year-on-year through AugustUBS views funding as a leading indicator for bookings in 2H26 and 1H27.
• Clinical CRO book-to-bill1.23x average; 1.31x weighted average in 2Q26Bookings are a key valuation and revenue-growth indicator.
• FSP adoption44% of survey respondents increased FSP use; 24% increased FSOFSP may have 20%-30% lower pricing and 300-500bp lower margins than FSO.
• CRO group valuation~22x NTM P/EUp from 15x in February and modestly above the 19.5x post-GFC average.
• CRL internal NHP sourcing benefit~$40M annualized FY27 savings; >160bp DSA margin expansion; ~$0.64 EPS accretionBased on a shift toward approximately 80% internally sourced NHP supply.

Impact & implications

UBS expects improving biotech funding and bookings to support a recovery in CRO revenue growth, but not a return to historical high-single-digit industry growth. It believes selectivity is warranted because FSP mix, pricing pressure, AI-related long-term uncertainty, and more demanding valuations reduce the scope for a broad sector re-rating. UBS therefore favors IQV's share gains and reasonable valuation, and CRL's identifiable NHP-sourcing earnings catalyst.

Risks

• Adverse clinical trial results, biotech-funding volatility, or lower biopharma R&D budgets could weaken CRO demand.
• Changes in pharmaceutical regulation across the FDA and global agencies could affect development activity.
• Geopolitical disruption could affect research sites, funding, or clinical-development activity.
• Continued FSP adoption, competitive pricing, and AI-related efficiency discounts could constrain CRO revenue and margins.
• AI could eventually reduce revenue per trial or commoditize services such as medical writing and biostatistics.

What to watch

• Whether biotech funding remains strong enough to support higher bookings and book-to-bill in 2H26 and 1H27.
• The FSO-versus-FSP outsourcing mix and whether sponsor behavior moves toward a more balanced mix.
• CRO book-to-bill, backlog conversion, bookings-recognition practices, and cancellations.
• Evidence that AI adoption creates volume benefits before it creates meaningful pricing or revenue-per-trial pressure.
• IQV's ability to sustain book-to-bill above 1.20x and CRL's realization of NHP-sourcing cost savings.
• FTRE's booking recovery, margin progress, normalized free cash flow, and deleveraging.